Needham & Company Maintains a 'Hold' on Endo Pharmaceuticals (ENDP); Solid 3Q11 Results Highlight Strength in Branded and Generic Pharma Business
Tweet
Share
E-mailGet Alerts ENDP Hot Sheet
Price: $0.29 --0%
Rating Summary:
14 Buy, 15 Hold, 5 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Rating Summary:
14 Buy, 15 Hold, 5 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 13 | Down: 14 | New: 11
Join SI Premium – FREE
Needham & Company maintains a 'Hold' on Endo Pharmaceuticals (NASDAQ: ENDP).
Needham analyst says, "ENDP’s 3Q11 delivered strong top- and bottom-line results that easily outpaced Street expectations. The pharma businesses (branded and generics) drove top-line strength, while the devices/services segment (Healthronics and AMS) had more muted growth due to prior safety issues and lower procedural volumes. The bottom-line was further aided by lower OpEx and non-operational metrics (tax rate and share count). Despite solid beat, ENDP reaffirmed its prior 2011 guidance, and gave itself flexibility in case of a slower than expected recovery of the devices/services segment. We remain at HOLD as EPS accretion related to recent acquisitions is now fully priced-in and investor focus shifts to synergy generation and revenue growth acceleration."
For more ratings news on Endo Pharmaceuticals click here and for the rating history of Endo Pharmaceuticals click here.
Shares of Endo Pharmaceuticals closed at $32.38 yesterday.
Needham analyst says, "ENDP’s 3Q11 delivered strong top- and bottom-line results that easily outpaced Street expectations. The pharma businesses (branded and generics) drove top-line strength, while the devices/services segment (Healthronics and AMS) had more muted growth due to prior safety issues and lower procedural volumes. The bottom-line was further aided by lower OpEx and non-operational metrics (tax rate and share count). Despite solid beat, ENDP reaffirmed its prior 2011 guidance, and gave itself flexibility in case of a slower than expected recovery of the devices/services segment. We remain at HOLD as EPS accretion related to recent acquisitions is now fully priced-in and investor focus shifts to synergy generation and revenue growth acceleration."
For more ratings news on Endo Pharmaceuticals click here and for the rating history of Endo Pharmaceuticals click here.
Shares of Endo Pharmaceuticals closed at $32.38 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Coherent (COHR) PT Raised to $420 at Needham
- Wolverine World Wide (WWW) PT Raised to $24 at Needham
- Coherent (COHR) PT Raised to $420 at Needham
Create E-mail Alert Related Categories
Analyst CommentsRelated Entities
Needham & CompanySign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
